OSI Pharmaceuticals (OSIP) - formerly Oncogene Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: sammaster who wrote (346)	1/18/2006 9:20:03 AM
From: DewDiligence_on_SI	of 447

smith barney gives no respect to macugen they dont even mention that drug as a competitor :) In terms of efficacy, off-label Avastin is indeed more of a Lucentis competitor than Macugen is. …not sure which doctors would be willing to place a chemo agent in the eye that is not approved besides the ones in teaching/research centers... Avastin is a cancer agent but it’s not considered a chemo agent. As the SB report mentions, Avastin’s use in AMD figures to be drastically reduced when Lucentis becomes available. Regards, Dew

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next